Michael Smith Net Worth

The estimated Net Worth of Michael David Smith is at least $80.4 Tausend dollars as of 1 June 2021. Mr. Smith owns over 7,500 units of KalVista Pharmaceuticals Inc stock worth over $80,400 and over the last 4 years he sold KALV stock worth over $0. In addition, he makes $0 as Senior Vice President - Development at KalVista Pharmaceuticals Inc.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Mr. Smith KALV stock SEC Form 4 insiders trading

Michael has made over 2 trades of the KalVista Pharmaceuticals Inc stock since 2021, according to the Form 4 filled with the SEC. Most recently he exercised 7,500 units of KALV stock worth $62,925 on 1 June 2021.

The largest trade he's ever made was exercising 10,014 units of KalVista Pharmaceuticals Inc stock on 28 April 2021 worth over $84,017. On average, Michael trades about 2,919 units every 6 days since 2020. As of 1 June 2021 he still owns at least 7,500 units of KalVista Pharmaceuticals Inc stock.

You can see the complete history of Mr. Smith stock trades at the bottom of the page.

Michael Smith biography

Michael D. Smith serves as Senior Vice President - Development of the Company. He served as the Vice President, Clinical Development of KalVista Limited since February 2016 and became our Vice President, Clinical Development as of November 2016, and was promoted to Senior Vice President, Development in May 2019. Prior to joining us, he was the Director, Scientific Affairs at PRA Health Sciences from July 2011 to February 2016. Prior to that, Dr. Smith worked as the Senior Manager, Clinical Development and Regulatory Affairs at ZARS Pharma. Dr. Smith also has served as an Adjunct Assistant Professor at the University of Utah since August 2014. Dr. Smith holds a B.Sc. from Brigham Young University and a Pharm.D. from the University of Utah.

How old is Michael Smith?

Michael Smith is 41, he's been the Senior Vice President - Development of KalVista Pharmaceuticals Inc since 2019. There are 17 older and no younger executives at KalVista Pharmaceuticals Inc. The oldest executive at KalVista Pharmaceuticals Inc is Arnold Oronsky, 80, who is the Independent Director.

What's Michael Smith's mailing address?

Michael's mailing address filed with the SEC is C/O KALVISTA PHARMACEUTICALS, INC, 55 CAMBRIDGE PARKWAY, SUITE 901E, CAMBRIDGE, MA, 02142.

Insiders trading at KalVista Pharmaceuticals Inc

Over the last 8 years, insiders at KalVista Pharmaceuticals Inc have traded over $74,823,944 worth of KalVista Pharmaceuticals Inc stock and bought 4,877,063 units worth $58,591,487 . The most active insiders traders include Holdings A/S Novo, Capital Management, L.P.Ra ... und Rajeev M. Shah. On average, KalVista Pharmaceuticals Inc executives and independent directors trade stock every 19 days with the average trade being worth of $835,088. The most recent stock trade was executed by Benjamin L Palleiko on 6 September 2024, trading 15,625 units of KALV stock currently worth $167,500.

What does KalVista Pharmaceuticals Inc do?

kalvista is a clinical stage pharmaceuticals company focused on the discovery, development, and commercialization of small molecule protease inhibitors.

Complete history of Mr. Smith stock trades at KalVista Pharmaceuticals Inc

KalVista Pharmaceuticals Inc executives and stock owners

KalVista Pharmaceuticals Inc executives and other stock owners filed with the SEC include:

• Thomas Crockett,
  Chief Executive Officer, Director
• Edward Feener,
  Chief Scientific Officer
• Benjamin Palleiko,
  Chief Financial Officer, Chief Business Officer
• Thomas Andrew Crockett M.B.A.,
  CEO & Director
• Christopher Yea,
  Chief Development Officer
• Benjamin L. Palleiko,
  Chief Bus. Officer & CFO
• Dr. Christopher M. Yea Ph.D.,
  Chief Devel. Officer
• Martin Edwards,
  Independent Chairman of the Board
• Edward Unkart,
  Independent Director
• Arnold Oronsky,
  Independent Director
• Albert Cha,
  Independent Director
• Brian Pereira,
  Independent Director
• Daniel Soland,
  Independent Director
• Michael Smith,
  Senior Vice President - Development
• Andreas Maetzel,
  Senior Vice President - Medical
• Jarrod Aldom,
  VP of Corp. Communications
• John B. McKune,
  VP of Fin.
• Stephen Donnelly,
  Director of Fin. and Company Sec.
• Dr. Paul K. Audhya M.B.A., M.D.,
  Chief Medical Officer
• Dr. Michael D. Smith Pharm.D.,
  Sr. VP of Devel.
• Rachel Morten,
  Head of Regulatory Affairs and QA
• Leah Monteiro,
  Sr. Director of Corp. Communications & Investor Relations
• Dr. Edward P. Feener Ph.D.,
  Chief Scientific Officer
• Joshua Resnick,
  Director
• Iv, Llcsv Life Sciences Fun...,
  
• Capital Management, Llc Kol...,
  
• Capital Management, L.P.Ra ...,
  
• Rajeev M. Shah,
  Director
• Healthcare Capital Partners...,
  
• Holdings A/S Novo,
  10% owner
• William Fairey,
  
• Paul K. Audhya,
  CHIEF MEDICAL OFFICER
• Healthcare Capital Partners...,
  
• Nancy Stuart,
  Director
• Patrick Treanor,
  Director
• Brian Piekos,
  Chief Financial Officer
• Healthcare Capital Partners...,